Actively Recruiting
Safety Evaluation of Patient-Derived Tumor-Infiltrating Lymphocytes for Recurrent Ovarian Cancer Treatment
Led by Yong Wha Moon · Updated on 2026-06-16
6
Participants Needed
1
Research Sites
25 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to assess the safety and effectiveness of autologous tumor-infiltrating lymphocytes TILs in treating recurrent ovarian cancer. The study focuses on evaluating both the potential benefits and risks of this treatment approach, involving participants who have a cancerous lesion suitable for biopsy or surgery. The trial is designed to provide important safety data and preliminary efficacy insights. Participants will have tumor tissue collected through biopsy or surgery to culture enhanced tumor-infiltrating lymphocytes. These cultured cells, called CHA-TIL, will then be administered as a single intravenous infusion. The study includes a treatment period lasting 2 months, followed by a 4-month follow-up to monitor safety and response to therapy. Throughout the trial, participants will be closely monitored with evaluations of the cells ability to attack cancer cells and assessments of treatment-related toxicity, including lymphodepletion, CHA-TIL infusion, and high-dose IL2 therapy. The total observation time covers 6 months from treatment start, during which various safety and efficacy measures will be collected to understand the treatments impact.
CONDITIONS
Brief Title
To Evaluate the Safety of Autologous Tumor-infiltrating Lymphocytes(TILs) for the Treatment of Recurrent Ovarian Cancer
Research Team
Y
Yong Wha Moon
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here